Komori
All About (2454) · FactRestated

R&D Expenses: ¥13 Million

First written in FY2022-Q3. 4 of 9 entries say "Restated". Latest entry: FY2026-H1.

9entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q3 – FY2026-H12022: 320222023: 320232024: 220242025: 12025
Same theme, other companies
Recognition and Disclosure of R&D ExpensesA theme 73 companies write about · 0 as a headwind · 21 as a tailwind

5 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 73 companies compared. The sentences above are computed from all 73.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「Not applicable.」

    The company continues to state that there were no applicable research and development activities during the interim consolidated accounting period.
  2. FY2025-H1RestatedAnnual report

    「(8) Research and development activities: Not applicable.」

    The company continues to state that there were no applicable research and development activities during the interim consolidated accounting period.
  3. FY2024-Q3RestatedAnnual report

    「(7) Research and development activities: Not applicable.」

    The company continues to state that there were no applicable research and development activities during the cumulative third quarter of the fiscal year.
  4. FY2024-Q2RestatedAnnual report

    「(8) Research and development activities: Not applicable.」

    The company reconfirms that there were no applicable research and development activities during the cumulative second quarter of the fiscal year.
  5. FY2024-Q1DroppedAnnual report

    「(7) Research and development activities: Not applicable.」

    The company explicitly states that there were no applicable research and development activities during the cumulative first quarter of the fiscal year.
  6. FY2023-Q3Research and development expenses: ¥6 millionAnnual report

    「The amount of R&D activity for the Group as a whole during the consolidated cumulative third quarter was ¥6 million.」

    The company disclosed research and development expenses of ¥6 million for the cumulative third quarter of the fiscal year.
  7. FY2023-Q2Research and development expenses: ¥4 millionAnnual report

    「The amount of R&D activity for the Group as a whole during the consolidated cumulative second quarter was ¥4 million.」

    The company disclosed research and development expenses of ¥4 million for the cumulative second quarter of the fiscal year.
  8. FY2023-Q1Research and development expenses: ¥2 millionAnnual report

    「The amount of R&D activity for the Group as a whole during the consolidated cumulative first quarter was ¥2 million.」

    The company disclosed research and development expenses of ¥2 million for the cumulative first quarter of the fiscal year.
  9. FY2022-Q3First statedAnnual report

    「The Group's total research and development activities during the nine-month period ended the third quarter amounted to ¥13 million.」

    The company disclosed Group-wide research and development expenses of ¥13 million for the nine-month period ended the third quarter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for All About yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
R&D Expenses: ¥13 Million | All About,Inc. (2454) | Komori